AMRI 4Q Revenues: $191.3 million (+51%) 4Q Loss: $15.4 million (earnings were $1.8 million 4Q15) FY Revenues: $570.5 million (+ 42%) FY Loss: $70.2 million (loss of $2.3 million FY15) Comments: Contract revenue for the quarter was $189.5 million, up 54%. Recurring royalty revenue was $1.9 million, down from $3.4 million in 4Q15, due primarily to a decline of in sales of certain amphetamine salts sold by Teva Pharmaceuticals, partially offset by the addition of royalties resulting ...